Wearable Injectors Market Size, Share & Trends Analysis Report By Type, By Technology (Spring-based, Motor-driven, Rotary Pump, Expanding Battery, Other), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global wearable injectors market size was valued at USD 7.65 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 15.3% from 2023 to 2030. The key factors driving the market include the prevalence of chronic illnesses, the rising geriatric population, and growing concern over needle stick injuries. In comparison to other medication delivery methods, wearable injectors are less expensive. Additionally, the desire to reduce healthcare expenditures and the rising demand for continuous monitoring and home-based treatment are anticipated to boost the demand for wearable injectors.

Additionally, strong healthcare infrastructure and an increase in lifestyle disorders are some of the factors driving market expansion. However, it is projected that low demand in developing economies and expensive wearable injectors could restrain the market's expansion in the upcoming years.

The COVID-19 pandemic boosted the demand for medical equipment and supplies, including wearable injectors. Additionally, several market participants engage in numerous projects that fuel market growth during the forecast period. Therefore, COVID-19 has had a favorably impacted the global wearable injectors market. The pandemic encouraged the healthcare systems to switch to home-based therapies to stop the spread of the sickness. Thus, considering the requirements, the companies are focusing on developing and manufacturing wearable injectors.

Needle stick injuries (NSIs) constitute the main occupational danger among healthcare workers. According to a a WHO study published in 2021, nearly 2 million of the 35 million healthcare professionals worldwide are exposed to occupational injuries each year. The danger of developing infectious diseases including HIV, hepatitis B, and hepatitis C is increased by needle stick injuries.

In addition, reports from the Centers for Disease Control and Prevention (CDC) and European Agency for Safety and Health at Work (EU-OSHA) indicate that healthcare workers in the U.S. & Europe, have about 3,85,000 & 1,000,000 needle stick injuries, respectively. Moreover, according to the World Health Organization, NSIs result in 16,000, 66,000, and 1,000 instances of HCV, HBV, and HIV among Health Care Workers (HCWs) annually.

With advanced injector technology, the patient is never in contact with a needle. After attaching the injector and pressing the button, the needle is inserted. The patient is alerted with tactile, audible, and visual indications as soon as the medicine is released, and the needle automatically retracts and locks out, permitting safe and convenient disposal of the device. With the use of wearable injectors, there would be no needle stick injuries as compared to intravenous injectable and parenteral administration.

Wearable injectors increase patient and healthcare worker safety by eliminating the dangers associated with traditional infusion and injection technology, such as drug preparation, needle insertion, covering, and disposal of needles.

However, one of the biggest problems emerging and developed countries face is the rise in healthcare costs. Countries strive to provide high-quality and affordable healthcare. Patients can self-administer wearable injectors subcutaneously at home with wearable injectors. It is anticipated to lower the frequency of trips to hospitals or other healthcare facilities, lowering healthcare costs.

Type Insights

The on-body wearable injectors accounted for the largest revenue share of 55.0% in 2022 owing to increased demand as these patches are comfortable to wear on the skin (stomach), water resistant and convenient to use at home The benefits associated with on-body wearable injectors are a decrease in the number of hospital visits as it decreases healthcare costs; lifecycle management; flexible dosing; and automatic warming of refrigerated drugs. Medtronic (Ireland) introduced an infusion set in April 2021 that allows for the transport of insulin from the pump to the body for a duration of up to seven days.

The off-body wearable injectors are expected to expand at a CAGR of 15.9% during the forecast period. These devices eliminate risks, such as painful removal of devices, adhesive fitting issues to the skin, and skin sensitivity or irritation. As a result of rising investments in the development of improved off-body, injectors are anticipated to boost the growth of this segment in the future.

Technology Insights

The spring-based wearable injectors segment held the largest share of 35.9% in 2022 and is expected to dominate throughout the forecast period. The market dominance is due to the user-friendliness and ability of the patients to precisely distribute the medication subcutaneously by pushing one or more buttons on the device. For instance, BD Libertas Wearable Injector is a pre-fillable and innovative drug delivery system offered by BD, a U.S.-based medical device company. It is integrated with a spring-based power source that eliminates the need for batteries or disposal of heavy metals.

The rotary pump wearable injectors segment is expected to grow at the fastest CAGR of 15.5% during the forecast period due to the increasing customer demand for these devices as they are more convenient for use than others.

End-use Insights

The home care segment led the market with a share of almost 41.8% in 2022. The market is growing due to rising demand for home-based healthcare and the requirement of advanced drug delivery devices requiring minimal expertise, and lesser hospitalization of the patients is expected to fuel the demand for wearable injectors globally.  Furthermore, the low cost of wearable injectors and the rising demand to cut healthcare expenses is expected to drive the home care segment. Moreover, according to a study, wearable injectors cost around USD 20 and USD 30, while infusion therapy ranges from USD 200 to USD 1,000 or more.

The hospital segment is expected to expand at a rapid rate owing to the rising prevalence of chronic disorders and the increased footfall of patients in hospitals for treatment.Oncology patients often require frequent administration of medications, which results in the need for regular hospital visits.

Specialized clinics are expanding. On-body injectors connected to cloud data enable physicians to track patient information and monitor drug adherence, which was previously managed during clinic visits. The integrated health model leads to an increase in the frequency of physician-patient interactions.

Application Insights

Oncology held the largest share of 29.5% in 2022. The oncology segment is likely to dominate the market owing to the rising prevalence of cancer coupled with increasing shift toward self-administration of medication among patients. Many drugs are available in the market today; however, to use them, a patient must visit a healthcare center frequently, leading to increased expenditure and discomfort. The Canadian Cancer Society estimates that in 2022, approximately 13% of Canadians will get lung and bronchus cancer, which would cause the death of 24% of all cancer patients. Due to the rising incidence of cancer and the tendency toward patients’ self-administering medication is rising.

The infectious disease segment is anticipated to grow at the fastest CAGR of 15.5% during the forecast period. The World Health Organization (WHO) reported that approximately 20 million annual deaths globally are caused by infectious diseases. The prevalence of emerging infectious diseases, which are new or affects more people than before, such as coronavirus, Ebola, Salmonella, Hepatitis A, and West Nile virus, increases the demand for injectors. The growing need for advanced drug delivery is one of the major factors driving the growth of the global market.

Regional Insights

North America accounted for the largest revenue share of 33.2% in 2022. It is attributed to the rising prevalence of chronic & lifestyle-related diseases and augmented healthcare infrastructure. According to the CDC, about 37 million Americans have diabetes, 90 to 95% of whom have type 2 diabetes.

Asia Pacific is expected to grow at a rapid CAGR of around 15.0 % during the forecast period as compared to other regions, which can be attributed to favorable government initiatives for the use of medical devices such as wearable injectors due to increasing geriatric population, increase in healthcare expenditure, and increase in awareness about wearable injectors in this region.

Key Companies & Market Share Insights

The market is fragmented with high competition at the global level as it has the presence of major key players. These players focus on growth strategies, such as new product launches, collaborations, partnerships, operational expansion, mergers & acquisitions, and patient awareness campaigns. For instance, in March 2021 Aptar and Noble International announced their collaboration with dne pharma, a pioneer in Northern European addiction treatment, in March 2021, using the innovative Unidose Liquid System developed by Ventizolve, Aptar, and Noble. The collaboration aims to prevent the potentially fatal effects of opioid overdose in Europe as soon as feasible.

In addition, numerous biopharmaceutical companies are seeking a better method of drug delivery of their own biological drugs, for which wearable injectors are a suitable solution. For instance, in April 2021, Medtronic plc made the first and only infusion set, the Medtronic Extended infusion set that can be worn for 7 days. Insulin is transferred into the body through a pump with the help of an infusion set. Furthermore, BD Libertas announced completing the human clinical trial of its BD Libertas Wearable Injector with 50 people in 2020. In 2022, Insulet Corporation announced the FDA approval of Omnipod 5, the first tubeless closed-loop insulin pump along with smartphone control. Some of the prominent players in the global wearable injectors market include:

• BD

• Johnson & Johnson Services, Inc.

• F. Hoffmann-La Roche Ltd.

• Unilife Corporation

• Steady Med Therapeutics, Inc.

• Amgen Inc.

• Insulet Corporation

• Enable Injections

• West Pharmaceutical Services, Inc.

• CeQur Simplicity

Wearable Injectors Market Report Scope

Global Wearable Injectors Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global wearable injectors market report based on the type, technology, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • On-body

  • Off-body

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Spring-based

  • Motor-driven

  • Rotary pump

  • Expanding battery

  • Other

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Infectious disease

  • Cardiovascular disease

  • Autoimmune disease

  • Immunodeficiency

  • Other

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Clinics

  • Home care

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait